Ikris Pharma Network Pvt. Ltd. and Orphan Europe S.A.R.L. have entered into agency agreement whereas Ikris Pharma Network will work as service partner to Orphan Europe and will help patients and doctors in accessing Orphan Europe products in India, Sri Lanka, Pakistan, Bangladesh and Nepal through Named Patient Import.
Orphan Europe ( www.orphan-europe.com), which was founded in 1990 and then acquired by Recordati ( www.recordati.com) in 2007, is a France based pharmaceutical company dedicated to research, development, manufacturing and marketing of drugs for rare diseases.
Ikris Pharma Network Pvt. Ltd., based out of NOIDA in DELHI-NCR; having Pan-India presence, is a fast growing, specialty pharmaceutical consultancy and service company with a unique business model dedicated to delivering medicines difficult to be procured to needy patients mostly in Asian countries.
The common denominator of rare diseases is the infrequency of their occurrence. Often debilitating lifelong disease or disorder with a prevalence of 1 or less, per 1000 population is defined by the World Health Organization (WHO) as a rare disease. According to Rare Diseases and Disorders – Research, Resource & Repository of South Asia*, there are more than 70 million patients suffering of rare diseases and disorders in India.
There are few pharmaceutical companies around the globe active in this field. Orphan Europe is dedicated to finding new treatments and improving the lives of people with rare diseases. Among other products Orphan Europe has achieved the approval by European Medicines Agency (EMA) for Carbaglu® (treatment of hyperammonemia associated to PA, MMA, IVA and NAGS deficiency), Cystagon® (treatment of nephropatic cystinosis), Cystadrops® (treatment of ocular manifestations of nephropatic cystinosis) and the approval by major European Agencies for Normosang® (treatment of Acute Hepatic Porphyrias).
“With the sign-off this agreement with Orphan Europe we will be able to bridge some gaps in unmet needs of the doctors in diagnosing, treating and managing patients with rare diseases. We will leverage our all India presence and strong networking within other Indian subcontinent countries with specialty doctors and disseminate the latest medical information about these rare diseases to the doctors” – says Mr. Praveen Sikri, the Founder & CEO of Ikris Pharma Network Pvt. Ltd. He further adds that – “Ikris will be the single point of contact for doctors & patients across India and Ikris will assist the patients in getting the medicine imported directly from Orphan Europe, once all local regulatory procedures for named-patient importation are fulfilled”.
Any doctor or patient who needs any information on products of Orphan Europe can reach Ikris Pharma Network Pvt. Ltd. at – email : firstname.lastname@example.org or call + 91 97172 00915.